178 related articles for article (PubMed ID: 25645856)
1. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
2. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
3. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Milner EE; Berman J; Caridha D; Dickson SP; Hickman M; Lee PJ; Marcsisin SR; Read LT; Roncal N; Vesely BA; Xie LH; Zhang J; Zhang P; Li Q
Malar J; 2016 Dec; 15(1):588. PubMed ID: 27923405
[TBL] [Abstract][Full Text] [Related]
6. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.
Marcsisin SR; Reichard G; Pybus BS
Pharmacol Ther; 2016 May; 161():1-10. PubMed ID: 27016470
[TBL] [Abstract][Full Text] [Related]
7. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
8. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Marcsisin SR; Sousa JC; Reichard GA; Caridha D; Zeng Q; Roncal N; McNulty R; Careagabarja J; Sciotti RJ; Bennett JW; Zottig VE; Deye G; Li Q; Read L; Hickman M; Dhammika Nanayakkara NP; Walker LA; Smith B; Melendez V; Pybus BS
Malar J; 2014 Jan; 13():2. PubMed ID: 24386891
[TBL] [Abstract][Full Text] [Related]
9. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
10.
Pett H; Bradley J; Okebe J; Dicko A; Tiono AB; Gonçalves BP; Stone W; Chen I; Lanke K; Neuvonen M; Mustaniemi AL; Eziefula AC; Gosling R; D'Alessandro U; Drakeley C; Niemi M; Bousema T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383656
[TBL] [Abstract][Full Text] [Related]
11. Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.
Fasinu PS; Tekwani BL; Avula B; Chaurasiya ND; Nanayakkara NP; Wang YH; Khan IA; Walker LA
Malar J; 2016 Sep; 15(1):466. PubMed ID: 27618912
[TBL] [Abstract][Full Text] [Related]
12. [Study of pharmacokinetics of liver targeting antimalarial agent neoglycoalbumin-primaquine conjugate (NGA-PQ) and primaquine phosphate in mouse].
Li TL; Pang QJ; He YL; Wang P
Yao Xue Xue Bao; 1995; 30(10):721-5. PubMed ID: 8701725
[TBL] [Abstract][Full Text] [Related]
13. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.
Pybus BS; Sousa JC; Jin X; Ferguson JA; Christian RE; Barnhart R; Vuong C; Sciotti RJ; Reichard GA; Kozar MP; Walker LA; Ohrt C; Melendez V
Malar J; 2012 Aug; 11():259. PubMed ID: 22856549
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective metabolism of primaquine by human CYP2D6.
Fasinu PS; Tekwani BL; Nanayakkara NP; Avula B; Herath HM; Wang YH; Adelli VR; Elsohly MA; Khan SI; Khan IA; Pybus BS; Marcsisin SR; Reichard GA; McChesney JD; Walker LA
Malar J; 2014 Dec; 13():507. PubMed ID: 25518709
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Li Q; O'Neil M; Xie L; Caridha D; Zeng Q; Zhang J; Pybus B; Hickman M; Melendez V
Malar J; 2014 Apr; 13():141. PubMed ID: 24731238
[TBL] [Abstract][Full Text] [Related]
16. Measurements of 5,6-Orthoquinone, a Surrogate for the Presumed Active Primaquine Metabolite 5-Hydroxyprimaquine, in the Urine of Cambodian Adults.
Vanachayangkul P; Sea D; Wojnarski M; Sok S; Kodchakorn C; Ta-Aksorn W; Hom S; Ittiverakul M; Kuntawunginn W; Arsanok M; Buathong N; Heng TK; Nareth K; Nou S; Chandara S; Ly S; Oung P; Vesely B; Bennett J; Reichard G; Pybus B; Lanteri C; Saunders D; Fukuda M; Smith P; Dysoley L; Rekol H; Waters NC; Spring M
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0182121. PubMed ID: 34978892
[TBL] [Abstract][Full Text] [Related]
17. Enantioselective pharmacokinetics of primaquine in healthy human volunteers.
Tekwani BL; Avula B; Sahu R; Chaurasiya ND; Khan SI; Jain S; Fasinu PS; Herath HM; Stanford D; Nanayakkara NP; McChesney JD; Yates TW; ElSohly MA; Khan IA; Walker LA
Drug Metab Dispos; 2015 Apr; 43(4):571-7. PubMed ID: 25637634
[TBL] [Abstract][Full Text] [Related]
18. Antimalarial activity of primaquine operates via a two-step biochemical relay.
Camarda G; Jirawatcharadech P; Priestley RS; Saif A; March S; Wong MHL; Leung S; Miller AB; Baker DA; Alano P; Paine MJI; Bhatia SN; O'Neill PM; Ward SA; Biagini GA
Nat Commun; 2019 Jul; 10(1):3226. PubMed ID: 31324806
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of primaquine in normal human volunteers: investigation of phase I and phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Avula B; Tekwani BL; Chaurasiya ND; Fasinu P; Dhammika Nanayakkara NP; Bhandara Herath HMT; Wang YH; Bae JY; Khan SI; Elsohly MA; McChesney JD; Zimmerman PA; Khan IA; Walker LA
Malar J; 2018 Aug; 17(1):294. PubMed ID: 30103751
[TBL] [Abstract][Full Text] [Related]
20. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
